search icon

    Market Snapshot

    • S&P Futures

      4,132

    • Dow Futures

      32,804

    • Nasdaq Futures

      13,053.75

    blog search icon

    Nektar Therapeutics

    (NASDAQ:NKTR)

    $4.79

    -$0.08

    -1.64%

    Nektar Therapeutics Chart

    NKTR Stock Price Today

    Nektar Therapeutics (NKTR) stock declined over -1.64% intraday to trade at $4.79 a share on NASDAQ. The stock opened with a gain of 14.87% at $4.57 and touched an intraday high of $4.945, falling -1.84% against the last close of $4.88. The stock went to a low of $4.6 during the session.

    Stock Snapshot

    $4.88

    Prev. Close

    821.62 Million

    Market Cap

    $4.6

    Day Low

    $4.57

    Open

    185.85 Million

    Number of Shares

    $4.945

    Day High

    -

    P/E ratio

    -2.83

    EPS (TTM)

    3.58

    Cash Flow per Share

    12.79

    Free Float in %

    4.34

    Book Value

    24,678

    Volume

    Nektar Therapeutics Historical Data

    DateOpenHighLowCloseVolume
    2022-08-08$4.57$4.945$4.6$4.873,693,001
    2022-08-05$4.17$4.91$4.15$4.882,410,000
    2022-08-04$4.43$4.55$4.32$4.421,962,500
    2022-08-03$4.08$4.47$4.07$4.473,060,500
    2022-08-02$3.74$4.03$3.72$4.031,904,600
    2022-08-01$3.91$3.94$3.77$3.771,772,800
    2022-07-29$4.01$4.12$3.88$3.962,174,700
    2022-07-28$4.12$4.18$3.91$4.051,704,200
    2022-07-27$3.98$4.12$3.87$4.121,909,200
    2022-07-26$3.7$3.97$3.67$3.941,959,500

    Contact Details

    455 Mission Bay Boulevard South
    San Francisco, CA 94158
    United States

    Webiste:NKTR

    415 482 5300

    Company Information

    Employees-

    Beta1.17

    Sales or Revenue103.08 Million

    5Y Sales Change-9.2%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryPharmaceuticals

    About Company

    Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

    Frequently Asked Questions

    icon

    What is the current Nektar Therapeutics (NKTR) stock price?

    Nektar Therapeutics (NASDAQ: NKTR) stock price is $4.79 as of the last check on Monday, August 8. During the trading session, NKTR stock reached the peak price of $4.945 while $4.6 was the lowest point it dropped to.

    icon

    NKTR's industry and sector of operation?

    The NASDAQ listed NKTR is part of Pharmaceuticals industry that operates in the broader Health Care sector. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

    icon

    Who are the executives of NKTR?

    Dr. Jonathan Zalevsky
    Chief R&D Officer
    Mr. Howard W. Robin
    CEO, Pres & Director
    Mr. Gilbert M. Labrucherie J.D.
    Sr. VP, CFO & COO
    Mr. Mark A. Wilson
    Sr. VP, Gen. Counsel & Sec.

    icon

    What is the NKTR stock price today?

    NKTR stock traded closed the last session at $4.87, which is -$0.08000000000000007 or -1.6427104722792623% lower than its previous close of $4.88. NKTR's current trading price is 61.26% lower than its 52-week high of $19.37 where as its distance from 52-week low of 3.02% is -74.86%.

    icon

    How many employees does NKTR have?

    Number of NKTR employees currently stands at -. NKTR operates from 455 Mission Bay Boulevard South, San Francisco, CA 94158, United States.

    icon

    Link for NKTR official website?

    Official Webiste of $NKTR is: https://www.nektar.com

    icon

    How do I contact NKTR?

    NKTR could be contacted at NKTR operates from 455 Mission Bay Boulevard South, San Francisco, CA 94158, United States, or at phone #415 482 5300 and can also be accessed through its website.

    icon

    How many shares of NKTR are traded daily?

    NKTR stock volume for the day was 24,678 shares while in the previous session number of NKTR shares traded was 3,693,001 . The average number of NKTR shares traded daily for last 3 months was 3.36 Million.

    icon

    How much did NKTR change today?

    The percentage change in NKTR stock occurred in the recent session was -1.6427104722792623% while the dollar amount for the price change in NKTR stock was -$0.08000000000000007.

    icon

    What price range NKTR stock been trading in?

    In the recent session, the day high for NKTR stock was $4.945 while the low for NKTR stock touched on the day was $4.6.

    icon

    What is the market cap of NKTR currently?

    The market value of NKTR currently stands at 821.62 Million with its latest stock price at $4.79 and 185.85 Million of its shares outstanding.